Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mircea Dediu"'
Autor:
Kenneth J. O'Byrne, Sergei M. Mikhailov, Helen J. Ross, Jack W. Singer, M. Smakal, Corey J. Langer, David F. Heigener, F. B. Oldham, Amy J. Eisenfeld, Larissa Sandalic, Mark A. Socinski, Tudor Ciuleanu, Krzysztof Leśniewski-Kmak, Mircea Dediu, Sergey Orlov
Publikováno v:
Journal of Thoracic Oncology. 3:623-630
Free to read at publisher's site. INTRODUCTION: Performance status (PS) 2 patients with non-small cell lung cancer (NSCLC) experience more toxicity, lower response rates, and shorter survival times than healthier patients treated with standard chemot
Autor:
Yong Jiang Hei, David R. Spigel, Keunchil Park, Rinat Galiulin, Natividad Martinez Banaclocha, Francesco Galimi, Oleksandr Sydorenko, Kaoru Kubota, Fiona H Blackhall, Robert Pirker, Giorgio V. Scagliotti, Ihor Vynnychenko, Mircea Dediu, Sheryl McCoy, Bin Yao, Yukito Ichinose, Tudor Ciuleanu, Zsolt Papai-Szekely
Purpose We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) vers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222c454ddddee6e7cb2f53863d935a4f
http://hdl.handle.net/2318/118283
http://hdl.handle.net/2318/118283
Autor:
Andrew Arnold, Natasha B. Leighl, Tudor-Eliade Ciuleanu, Lesley Seymour, Mark D. Vincent, Frances A. Shepherd, David Fenton, Scott A. Laurie, Eliot Frymire, David Walde, I. Gauthier, Keyue Ding, Francis Laberge, Glenwood D. Goss, Christopher W. Lee, Mauro Zukin, Cheryl Ho, Jonathan Noble, Mircea Dediu, Peter M. Ellis
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(1)
Purpose This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced non–small-cell lung cancer (NSCLC). Patients and Methods Paclitaxel (200 mg/m2) and carboplatin (area
Autor:
Martin Reck, Tudor Ciuleanu, Coleman K. Obasaju, Nina Karaseva, Susan C. Guba, Shengyan Hong, Egbert F. Smit, Nick Thatcher, Kartik Konduri, Johnetta Blakely, Carla Visseren-Grul, Aleksandra Szczesna, Jacek Jassem, Paul Lorigan, Mircea Dediu, Axel Hanauske, Piotr Serwatowski, Mark A. Socinski
Publikováno v:
Socinski, MA, Smit, E F, Lorigan, P, Konduri, K, Reck, M, Szczesna, A, Blakely, J, Serwatowski, P, Karaseva, N A, Ciuleanu, T, Jassem, J, Dediu, M, Hong, SH, Visseren-Grul, C, Hanauske, A R, Obasaju, C K, Guba, S C & Thatcher, N 2009, ' Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer ', Journal of Clinical Oncology, vol. 27, no. 28, pp. 4787-4792 . https://doi.org/10.1200/JCO.2009.23.1548
Journal of Clinical Oncology, 27(28), 4787-4792. American Society of Clinical Oncology
Journal of Clinical Oncology, 27(28), 4787-4792. American Society of Clinical Oncology
Purpose Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to that of historical etoposide-platinum controls, a phase III study was conducted to compare pemetrexed-carboplatin with etoposide-carboplatin for the trea
Autor:
Mircea Dediu
Publikováno v:
Lung Cancer. 36:217-218
As most of the oncologists dealing with small cell lung cancer (SCLC) are aware, no important progresses have been made within the last 20 years. Thus any advance in this field, especially concerning the chemotherapy regimens, should be regarded with